Compile Data Set for Download or QSAR
Report error Found 52 Enz. Inhib. hit(s) with all data for entry = 9803
TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 0.200nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267407(US9718822, 3 | US9750744, Example 3 | US9902741, E...)
Affinity DataIC50: 0.300nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM50507492(Loxo-195 | Selitrectinib | US10966985, Compound 33...)
Affinity DataIC50: 0.5nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 0.5nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267414(US9718822, 7 | US9750744, Example 7 | US9902741, E...)
Affinity DataIC50: 0.600nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 0.700nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267407(US9718822, 3 | US9750744, Example 3 | US9902741, E...)
Affinity DataIC50: 1.20nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267407(US9718822, 3 | US9750744, Example 3 | US9902741, E...)
Affinity DataIC50: 1.20nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267434(US9718822, 19 | US9750744, Example 19 | US9902741,...)
Affinity DataIC50: 1.20nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267416(US9718822, 9 | US9718822, 10 | US9750744, Example ...)
Affinity DataIC50: 1.70nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267436(US9718822, 20 | US9750744, Example 20 | US9902741,...)
Affinity DataIC50: 2.20nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267434(US9718822, 19 | US9750744, Example 19 | US9902741,...)
Affinity DataIC50: 2.40nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267434(US9718822, 19 | US9750744, Example 19 | US9902741,...)
Affinity DataIC50: 2.40nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267436(US9718822, 20 | US9750744, Example 20 | US9902741,...)
Affinity DataIC50: 2.5nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM50507492(Loxo-195 | Selitrectinib | US10966985, Compound 33...)
Affinity DataIC50: 2.70nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267436(US9718822, 20 | US9750744, Example 20 | US9902741,...)
Affinity DataIC50: 2.80nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267414(US9718822, 7 | US9750744, Example 7 | US9902741, E...)
Affinity DataIC50: 2.90nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267414(US9718822, 7 | US9750744, Example 7 | US9902741, E...)
Affinity DataIC50: 3.10nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM50507492(Loxo-195 | Selitrectinib | US10966985, Compound 33...)
Affinity DataIC50: 3.60nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267469(US9718822, 45 Diastereomer 1 | US9750744, Example ...)
Affinity DataIC50: 4.60nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267469(US9718822, 45 Diastereomer 1 | US9750744, Example ...)
Affinity DataIC50: 6.10nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 6.5nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 7.60nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267416(US9718822, 9 | US9718822, 10 | US9750744, Example ...)
Affinity DataIC50: 9.20nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM267407(US9718822, 3 | US9750744, Example 3 | US9902741, E...)
Affinity DataIC50: 9.40nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267416(US9718822, 9 | US9718822, 10 | US9750744, Example ...)
Affinity DataIC50: 10.2nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM266501(US9718822, 2 | US9750744, Example 2 | US9902741, E...)
Affinity DataIC50: 11.9nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM446757((6R,15S)-9-fluoro-15-methyl- 2,11,16,20,21,24- hex...)
Affinity DataIC50: 14.3nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM267434(US9718822, 19 | US9750744, Example 19 | US9902741,...)
Affinity DataIC50: 14.4nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267469(US9718822, 45 Diastereomer 1 | US9750744, Example ...)
Affinity DataIC50: 16.8nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM446757((6R,15S)-9-fluoro-15-methyl- 2,11,16,20,21,24- hex...)
Affinity DataIC50: 19.2nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM446757((6R,15S)-9-fluoro-15-methyl- 2,11,16,20,21,24- hex...)
Affinity DataIC50: 19.6nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM50507492(Loxo-195 | Selitrectinib | US10966985, Compound 33...)
Affinity DataIC50: 20.4nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM267436(US9718822, 20 | US9750744, Example 20 | US9902741,...)
Affinity DataIC50: 21.6nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 28.9nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM267414(US9718822, 7 | US9750744, Example 7 | US9902741, E...)
Affinity DataIC50: 29.2nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 30.3nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM266501(US9718822, 2 | US9750744, Example 2 | US9902741, E...)
Affinity DataIC50: 67nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM266501(US9718822, 2 | US9750744, Example 2 | US9902741, E...)
Affinity DataIC50: 80.3nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM267416(US9718822, 9 | US9718822, 10 | US9750744, Example ...)
Affinity DataIC50: 98.6nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM267424(US9718822, 14 | US9750744, Example 14 | US9902741,...)
Affinity DataIC50: 107nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM267469(US9718822, 45 Diastereomer 1 | US9750744, Example ...)
Affinity DataIC50: 114nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM446757((6R,15S)-9-fluoro-15-methyl- 2,11,16,20,21,24- hex...)
Affinity DataIC50: 157nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267452(US9718822, 35 | US9750744, Example 35 | US9902741,...)
Affinity DataIC50: 260nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267438(US9718822, 22 | US9750744, Example 22 | US9902741,...)
Affinity DataIC50: 331nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267438(US9718822, 22 | US9750744, Example 22 | US9902741,...)
Affinity DataIC50: 397nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267452(US9718822, 35 | US9750744, Example 35 | US9902741,...)
Affinity DataIC50: 589nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267438(US9718822, 22 | US9750744, Example 22 | US9902741,...)
Affinity DataIC50: 713nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267452(US9718822, 35 | US9750744, Example 35 | US9902741,...)
Affinity DataIC50: 779nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM266501(US9718822, 2 | US9750744, Example 2 | US9902741, E...)
Affinity DataIC50: 1.06E+3nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 52 total ) | Next | Last >>
Jump to: